文献速递中医内科中药与中成药合理使用

扶正化瘀方通过抑制EGFR信号通路改善四氯化碳诱导的肝纤维化

A herbal product inhibits carbon tetrachloride-induced liver fibrosis by suppressing the epidermal growth factor receptor signaling pathway.
PubMed 文献 · J Ethnopharmacol · 2023-03-30

扶正化瘀方由丹参、冬虫夏草、桃仁、松花粉、绞股蓝和五味子组成,临床显示对肝纤维化有益。本研究采用网络药理学预测、血清蛋白质组学验证及体内外实验,发现扶正化瘀方通过下调活化肝星状细胞中的EGFR信号通路抑制四氯化碳诱导的肝纤维化。

要点

  • 扶正化瘀方可减轻四氯化碳诱导的肝纤维化,降低α-SMA阳性肝星状细胞中p-EGFR表达。
  • 扶正化瘀方抑制EGFR下游ERK信号通路,并抑制EGF诱导的肝星状细胞活化。
  • 网络药理学筛选出175个扶正化瘀方-肝纤维化交叉蛋白作为潜在靶点。

核心结论

  • 扶正化瘀方对四氯化碳诱导的肝纤维化有良好效果,机制与下调活化肝星状细胞中EGFR信号通路有关。

研究设计与样本

  • 研究采用网络药理学分析、血清蛋白质组学验证,以及体内四氯化碳诱导模型和体外实验验证。

主要发现

  • 网络药理学分析筛选出175个扶正化瘀方-肝纤维化交叉蛋白,并确定EGFR信号通路为潜在靶点。
  • 体内实验发现扶正化瘀方可减轻四氯化碳诱导的肝纤维化,降低α-SMA阳性肝星状细胞中p-EGFR表达,并抑制肝脏组织中EGFR下游ERK信号通路。
  • 体外实验表明扶正化瘀方可抑制EGF诱导的肝星状细胞活化,以及p-EGFR和ERK信号通路关键蛋白的表达。

关键数值与推荐

  • 网络药理学分析共筛选出175个扶正化瘀方-肝纤维化交叉蛋白,并富集于EGFR信号通路。

临床怎么用

  • 扶正化瘀方可能通过抑制肝星状细胞中EGFR/ERK信号通路发挥抗肝纤维化作用,为临床应用提供机制依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Fuzheng Huayu formula (FZHY), composed of Salvia miltiorrhiza Bunge, Cordyceps sinensis, the seed of Prunus persica (L.) Batsch, the pollen of Pinus massoniana Lamb, Gynostemma pentaphyllum (Thunb.) Makino and the fruit of Schisandra chinensis (Turcz.) Baill, is a Chinese herbal compound with demonstrated clinical benefits in liver fibrosis (LF). However, its potential mechanism and molecular targets remain to be elucidated. AIM OF THE STUDY: This study was designed to evaluate the anti-fibrotic role of FZHY in hepatic fibrosis and to elucidate the potential mechanisms. MATERIALS AND METHODS: Network pharmacology was assayed to identify the interrelationships among compounds of FZHY, potential targets and putative pathways on anti-LF. Then the core pharmaceutical target for FZHY against LF was verified by serum proteomic analysis. Further in vivo and in vitro assays were performed to verify the prediction of the pharmaceutical network. RESULTS: The network pharmacology analysis revealed that a total of 175 FZHY-LF crossover proteins were filtered into a protein-protein interaction (PPI) network complex and designated as the potential targets of FZHY against LF, and the Epidermal Growth Factor Receptor (EGFR) signaling pathway was further explored according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Then analytical studies were validated by carbon tetrachloride (CCl4)-induced model in vivo. We found FZHY could attenuate CCl4-induced LF, especially decrease p-EGFR expression in α-Smooth Muscle Actin (α-SMA)-positive hepatic stellate cell (HSC) and inhibit the downstream of the EGFR signaling pathway, especially Extracellular Regulated Protein Kinases (ERK) signaling pathway in liver tissue. We further demonstrate that FZHY could inhibit Epidermal Growth Factor (EGF)-induced HSC activation, as well as the expression of p-EGFR and the key protein of the ERK signaling pathway. CONCLUSIONS: FZHY has a good effect against CCl4-induced LF. The action mechanism was associated with the down-regulation of the EGFR signaling pathway in activated HSCs.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Qi J, Ping D, Sun X, et al. A herbal product inhibits carbon tetrachloride-induced liver fibrosis by suppressing the epidermal growth factor receptor signaling pathway. J Ethnopharmacol. 2023. PMID: 37003405. doi:10.1016/j.jep.2023.116419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。